'Do not eat': Aldi apologises to shoppers as food recalled due to health risks
Aldi has issued a recall and apologised to its customers as one of its products poses a potential health risk to shoppers.
The Food Standards Agency (FSA) has warned any Aldi customers who have purchased the affected food not to eat it.
The supermarket chain is recalling its Inspired Cuisine Baby Potatoes with Herbs and Butter because it contains milk which is not mentioned on the label.
The packaging error means the product is a possible health risk to anyone with an allergy or an intolerance to milk or milk constituents.
Tuesday 24 June 2025 - Aldi recalls Inspired Cuisine Baby Potatoes with Herbs and Butter because of undeclared milk #FoodAllergy https://t.co/EiWbo9tA8C pic.twitter.com/2k4fSE3twx
— Food Standards Agency (@foodgov) June 24, 2025
The affected potatoes come in packs of 385g and have use by dates up to and including July 1.
A spokesman for the FSA said: 'Aldi is recalling the above product from customers and has been advised to contact the relevant allergy support organisations, which will tell their members about the recall.
'The company has also issued a point-of-sale notice to its customers. These notices explain to customers why the product is being recalled and tell them what to do if they have bought the product.
'If you have bought the above product and have an allergy or intolerance to milk or milk constituents, do not eat it.
'Instead return it to the store from where it was bought for a full refund. For more information, please visit https://help.aldi.co.uk/s/ or call customer services on 0800 042 0800.'
Asda, Matalan and Amazon recalls as shoppers told 'stop using them immediately'
FSA issues 'do not eat' warning over chocolate that may be a 'food safety risk'
'Do not eat' warning issued as 'unsafe to eat' sweets recalled
An Aldi spokesman added: 'We apologise that this product did not meet our normal high standards and thank you for your co-operation.'
If there is a problem with a food product that means it should not be sold, then it might be 'withdrawn' (taken off the shelves) or 'recalled' (when customers are asked to return the product).
The FSA issues Product Withdrawal Information Notices and Product Recall Information Notices to let consumers and local authorities know about problems associated with food.
In some cases, a 'Food Alert for Action' is issued.
This provides local authorities with details of specific actions to be taken on behalf of consumers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CVS Health Corporation (CVS): A Bull Case Theory
We came across a bullish thesis on CVS Health Corporation on Microcapexpert's Substack. In this article, we will summarize the bull's thesis on CVS. CVS Health Corporation's share was trading at $67.58 as of June 24th. CVS's trailing and forward P/E ratios were 16.13 and 11.49, respectively, according to Yahoo Finance. A healthcare professional in a meeting with a patient discussing care options using digital technology. The UK's Competition and Markets Authority (CMA) has published its initial findings on the veterinary services market, and the proposed remedies appear relatively mild for CVS Group. While the CMA highlights the need for improved price transparency, there are no indications of harsh regulatory actions that could threaten CVS's profitability or operational structure. This early outcome validates previous expectations that the regulatory scrutiny would result in limited disruption. Although these are not yet the CMA's final conclusions—with a full report expected in the coming months—the working paper offers a reliable preview of the ultimate resolution. With the regulatory overhang easing, investor sentiment has improved significantly. CVS's share price jumped 12% on the news and has now surged 50% since the start of the year. Despite this rebound, the stock still trades below the 2,000 pence level it held prior to the launch of the CMA investigation, suggesting more upside may lie ahead as the market fully digests the benign regulatory outcome. The stock's momentum is likely to continue as clarity returns and investors reprice the reduced risk profile. In the absence of severe restrictions, CVS can continue leveraging its scale and efficiencies in the UK veterinary market, and with regulatory uncertainty fading, valuation multiples may expand. For investors who were cautious due to regulatory concerns, this working paper signals a potential green light to reenter. Overall, CVS stands to benefit as regulatory fears dissipate and the market acknowledges the limited impact of the CMA's review. Previously, we covered a on CVS Health Corporation by Hidden Market Gems in April 2025, which highlighted its U.S.-centric revenues, essential offerings, and strong cash flow. The company's stock has depreciated ~4% since our coverage, as macro pressures persisted. The thesis still stands. Microcapexpert shares a similar view but emphasizes the regulatory clarity as a new catalyst. CVS Health Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 73 hedge fund portfolios held CVS at the end of the first quarter, which was 74 in the previous quarter. While we acknowledge the risk and potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
7 hours ago
- Medscape
NICE Backs Leadless Pacemakers for Some Heart Patients
The National Institute for Health and Care Excellence (NICE) has provisionally recommended leadless cardiac pacemaker implantation for patients with bradyarrhythmias who require single-chamber pacing. In draft guidance, NICE said there was insufficient evidence to support their use for dual-chamber pacing outside of research settings. Benefits Over Traditional Pacemakers The recommendation is based on an evidence review involving over one million patients across multiple studies. These included a randomised controlled trial, four systematic reviews with meta-analyses, five registry studies, four prospective studies, and two retrospective studies. Leadless pacemakers were found to be effective at detecting abnormal heart rhythms, restoring normal pacing, and improving quality of life. Unlike conventional transvenous pacemakers (TVPs), they do not require a chest incision, reducing the risk of infection and other complications, the regulator noted. 'The evidence demonstrates that leadless pacemakers can effectively regulate heart rhythm while reducing the risk of complications associated with traditional pacemakers, particularly infections and lead-related issues,' said Dr Anastasia Chalkidou, HealthTech programme director at NICE. How Leadless Pacemakers Work Bradyarrhythmias, which affect around 1 in 1000 people are typically treated with TVPs. These devices consist of a subcutaneous pacemaker box and leads that connect to the heart. For single-chamber leadless pacemakers, the proximal end is attached to a deflectable delivery catheter system. It is usually inserted percutaneously through the femoral or jugular vein using an introducer sheath. It is then moved into the right atrium, through the tricuspid valve, and into the right ventricle. Dual-chamber systems, which are still under evaluation, involve placing two devices — one in the right atrium and another in the right ventricle — during a single procedure. NICE highlighted that TVPs are known to carry risks, including lead failure and generator-related complications. Leadless pacemaker implantation may be preferable for patients with a history of device infection, endocarditis, immunosuppression, limited vascular access, or high infection risk. Call for Further Research While the draft guidance supports leadless pacemakers for single-chamber pacing, NICE said that more evidence is needed before endorsing their wider use. This includes research on patient selection — such as age, comorbidities, and the underlying cause of bradyarrhythmia — as well as data on implantation sites and clinical outcomes. Long-term durability of leadless devices also remains an area for investigation. 'The incidence of bradyarrhythmias increases with age, making this guidance particularly relevant to our ageing population,' said Professor Tom Clutton-Brock, chair of NICE's interventional procedures advisory committee. The draft guidance is open for public consultation until 23 July 2025. The advisory committee will meet again on 11 September 2025 to review feedback and finalise recommendations.
Bloomberg
7 hours ago
- Bloomberg
Cyberattack on UK Health Firm Contributed to Patient Death
A cyberattack that caused disruption at hospitals in London last year contributed to the death of a patient, health officials have confirmed for the first time. The incident occurred after a Russian hacking gang in June 2024 targeted Synnovis, a contractor that provides blood testing, transfusion and other pathology services to the UK's National Health Service, or NHS. The breach triggered a major crisis at health-care providers predominantly in the southeast of the city.
